Groupe Dynamite and Pfizer Report Third Quarter Earnings and Future Projections

  • 📰 globeandmail
  • ⏱ Reading Time:
  • 71 sec. here
  • 12 min. at publisher
  • 📊 Quality Score:
  • News: 63%
  • Publisher: 92%

BUSINESS ข่าว

GROUPE DYNAMITE,EARNINGS,PROFITS

Groupe Dynamite exceeded third-quarter profit expectations, while Pfizer offered a cautiously optimistic outlook for 2025 despite facing criticism from investors.

Groupe Dynamite reported a profit of $40.4 million in its third quarter, up from $34.9 million in the same quarter last year. Chief executive and chair Andrew Lutfy says that following a strong summer season, the company’s momentum continued into the third quarter with strong revenue and comparable store sales growth. The company, which made its debut on the Toronto Stock Exchange last month, says the profit amounted to 38 cents per diluted share for the quarter ended Nov.

2, up from 32 cents per diluted share a year earlier. Revenue for the quarter totalled $258.8-million, up from $220.1-million in the same quarter last year.On an adjusted basis, Groupe Dynamite says it earned 41 cents per diluted share, up from an adjusted profit of 33 cents per diluted share a year earlier. Pfizer also reported on Tuesday forecast 2025 profits roughly in line with Wall Street expectations, offering some relief to investors after a tumultuous year during which it attracted criticism from activist hedge fund Starboard Value. Shares of Pfizer rose after the drugmaker also said it was expecting 2025 sales of its COVID-19 vaccine and drug to be consistent with 2024 levels. The company expects adjusted profit of US$2.80 to US$3 per share, compared with analysts’ average estimate of US$2.88 per share, according to data compiled by LSEG. Pfizer has been reining in costs and shedding non-core businesses to pay down debt as it rebuilds itself after a sharp slump in sales of COVID-19 products. Its shares have fallen nearly 12 per cent this year and trade at less than half their value during the peak of the COVID-19 pandemic. That has left it open to investor criticism, with Starboard in October saying that Pfizer’s management has over-spent on big acquisitions and failed to produce profitable new drugs from those deals or from its internal research and development

เราได้สรุปข่าวนี้มาให้อ่านอย่างรวดเร็ว หากสนใจข่าว สามารถอ่านฉบับเต็มได้ที่นี่ อ่านเพิ่มเติม:

 /  🏆 5. in TH
 

ขอบคุณสำหรับความคิดเห็นของคุณ ความคิดเห็นของคุณจะถูกเผยแพร่หลังจากได้รับการตรวจสอบแล้ว

ประเทศไทย ข่าวล่าสุด, ประเทศไทย หัวข้อข่าว

Similar News:คุณยังสามารถอ่านข่าวที่คล้ายกันนี้ซึ่งเรารวบรวมจากแหล่งข่าวอื่น ๆ ได้

Groupe Dynamite Reports Strong Third Quarter EarningsGroupe Dynamite Inc. announced a 15.8% increase in third-quarter earnings, driven by robust revenue growth and comparable store sales.
แหล่ง: SooToday - 🏆 8. / 85 อ่านเพิ่มเติม »

Dynamite, Garage parent company makes debut on Toronto Stock ExchangeGroupe Dynamite Inc. kicked off its first day of trading on the Toronto Stock Exchange.
แหล่ง: CTVNews - 🏆 1. / 99 อ่านเพิ่มเติม »